BRIEF

on Hangzhou Diagens Biotechnology (HKG:2526)

DIAGENS Achieves New Milestones in Medical Imaging AI

DIAGENS, a leader in medical imaging AI, has unveiled benchmark results for its iMed-6.0 foundation model. The company has also introduced a new CT model capable of analyzing 509 diseases and imaging findings. The iMed-6.0 Thoth ranked first in MedBench's multimodal API evaluation, with the Aegis model following closely. Together, they excelled in core categories, reinforcing DIAGENS' prowess in medical visual perception and clinical decision support.

The CT model, optimized for chest and abdominal examinations, achieves a macro-averaged AUC of 0.855 for classification. Its precise capabilities promise to enhance diagnostic accuracy across numerous clinical applications. DIAGENS uses its iMedLoop™ platform to support specialty AI development, democratizing access to advanced medical AI tools for clinicians.

Financially, DIAGENS reported RMB 108.7 million in revenue for the first half of 2026, marking a 21% growth year-over-year. Its Model-as-a-Service segment contributed significantly, reflecting increased adoption of AI in healthcare institutions globally.

R. P.

Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.

Click here to consult the press release on which this article is based

See all Hangzhou Diagens Biotechnology news